Welcome to our dedicated page for HeartSciences SEC filings (Ticker: HSCSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HeartSciences Inc. (HSCSW) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that provide insight into its business as a healthcare information technology and medical technology company focused on AI-enhanced ECGs. These SEC filings cover its Nasdaq-listed common stock (HSCS) and warrants (HSCSW) and document regulatory, financial, and corporate events.
Through current reports on Form 8-K, HeartSciences discloses material developments such as amendments to its Equity Distribution Agreement for at-the-market offerings, progress and terms of its Regulation A unit offering, exchanges of debt into equity, and changes to its bylaws. Filings also reference press releases announcing financial results, business updates, and regulatory milestones, including FDA Breakthrough Device designation for an aortic stenosis ECG algorithm and the submission of the MyoVista wavECG device for 510(k) clearance.
Other 8-K filings describe Nasdaq listing matters, including a notice that the company had regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Governance-related filings detail amendments to the company’s equity incentive plan and grants of restricted stock units and stock options tied to regulatory and product milestones.
On Stock Titan’s filings page, users can review these documents alongside AI-powered summaries that explain the significance of each report. Investors can quickly locate quarterly and annual reports referenced in the 8-Ks, track capital-raising activities, and monitor warrant-related disclosures connected to the HSCSW symbol. Real-time updates from EDGAR and AI-generated highlights help readers understand how HeartSciences’ regulatory filings relate to its AI-ECG technology, MyoVista platforms, and Nasdaq-listed securities.
HeartSciences Inc. reported fiscal third-quarter 2026 results and shared a business update. The healthcare IT company is focused on commercializing its MyoVista Insights ECG platform and has submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance, an important regulatory milestone.
The company reported no meaningful revenue for the quarter as it continues investing in commercialization. As of January 31, 2026, it held approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity. Full financial details are available in its Form 10-Q for the same period.
HeartSciences Inc. reported another loss-making quarter for the period ended January 31, 2026, with a nine‑month net loss of $6.4 million and minimal revenue of $4,319. Operating expenses were driven by research and development and general and administrative costs, while interest expense added further pressure.
Cash and cash equivalents were $3.4 million against $7.6 million in total assets and $4.9 million in total liabilities, leaving stockholders’ equity at $2.7 million. The company discloses substantial doubt about its ability to continue as a going concern and is relying on external financing, including a $3.6 million Streeterville note and a Series D preferred stock offering that raised about $6.7 million.
HeartSciences Inc. reports that it has regained compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement, which calls for at least $2.5 million in stockholders’ equity for companies on The Nasdaq Capital Market. Nasdaq’s Listing Qualifications Staff notified the company on September 16, 2025, that the issue is resolved and the matter is now closed. HeartSciences had previously submitted a plan to Nasdaq explaining how it would regain and maintain compliance after falling below the required equity level.
HeartSciences Inc. filed a current report to furnish a press release covering its financial and operating results for the quarter ended July 31, 2025, along with other business updates. The press release is included as Exhibit 99.1 and is incorporated by reference in this report. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities filings.
HeartSciences, Inc. reported financing activity, corporate actions and development progress for its MyoVista wav ECG and cloud platform. The company completed a 100-for-1 reverse stock split and issued Units consisting of Series D Preferred Stock plus warrants, selling 1,317,689 Units for gross proceeds of approximately $4.6 million during the quarter and an additional 238,720 Units for approximately $0.8 million subsequent to period end, with up to $15.0 million available under the offering. Common shares outstanding increased to 2,281,054 as of July 31, 2025 from 1,119,107 on April 30, 2025. The company is preparing FDA submissions for the MyoVista wav ECG but does not yet have FDA clearances for AI-ECG algorithms. Inventory related to finished devices will be updated for limited field studies and may require additional write-downs if FDA clearance or market acceptance is not obtained. The company has loan obligations totaling $1.0 million from related-party lenders that accrue interest at 12% per annum (default 18%) and are secured by substantially all assets. HeartSciences currently notes a Nasdaq listing deficiency and is taking steps to regain compliance.
HeartSciences Inc. reports progress on its Regulation A offering and a related debt exchange that change its mix of cash, debt, and equity. The company’s qualified Form 1-A allows an offering of up to 4,285,714 units at $3.50 per unit, for a maximum of $15,000,000. Each unit includes one share of Series D preferred stock and a warrant to buy one share of common stock at $5.00 per share.
As of August 22, 2025, HeartSciences has received $5.2 million of gross proceeds, issuing 1,484,440 units. Holders of 979,851 Series D preferred shares have already converted them into 979,851 common shares. Separately, the company has exchanged $1,655,000 of an unsecured promissory note for 461,572 common shares, reducing that note’s principal. After these transactions, 2,535,066 common shares are issued and outstanding as of August 22, 2025.
HeartSciences Inc. (Nasdaq: HSCS) filed Prospectus Supplement No. 3 to update its at-the-market (ATM) program with Maxim Group. The Third Amendment to the September 2023 Equity Distribution Agreement lifts the program’s ceiling to $25 million; however, because the company’s non-affiliate public float is only $13.0 million, General Instruction I.B.6 of Form S-3 caps the immediate raise at $14,737,609. To date, 530,057 shares have been sold for ≈$10.4 million.
Maxim will earn a 4.0 % commission on gross proceeds up to $11.0 million and 3.0 % thereafter. The ATM will terminate upon sale of all registered shares, or may be ended at any time by either party. Shares will be offered “at-the-market” on Nasdaq; the last reported price on 31-Jul-2025 was $3.12 per share, while IPO warrants (HSCSW) traded at $0.1184.
The filing notes that no securities have been sold under I.B.6 limitations in the preceding 12 months. If HeartSciences’ public float exceeds $75 million, Form S-3 restrictions will fall away, enabling larger primary offerings. Investors are reminded to review the company’s risk factors incorporated by reference from its latest 10-K and 10-Q.